The Skinny on Upcoming Obesity FDA Meetings
Motley Fool
Is 2012 Make or Break for Cell Therapeutics?
Motley Fool
Cell Therapeutics' Wild Week
Motley Fool
22 Hot Drugs Facing FDA Approval in 2012
TheStreet.com
- Amarin
- Amgen
- AMR101
- Amylin
- Ariad
- Avanafil
- Bio-T-Gel
- Biogen Idec
- BioSante
- Bristol-Myers Squibb
- Bydureon
- Carfilzomib
- Cell Therapeutics
- Chelsea Therapeutics
- Corcept Therapeutics
- Corlux
- Curis
- Dapagliflozin
- Discovery Labs
- Elan
- Eliquis
- Ironwood
- Kalydeco
- Levadex
- linaclotide
- MAP Pharmaceuticals
- Merck
- Northera
- ONYX Pharmaceuticals
- Pfizer
- pixantrone
- Protalix BioTherapeutics
- Qnexa
- ridaforolimus
- Roche
- Surfaxin
- Teva Pharmaceuticals
- Tysabri
- Uplypso
- Vertex
- vismodegib
- Vivus
- Xgeva
Cell Therapeutics Efforts Validated
Yahoo/Zacks
Good News for Cell Therapeutics
Yahoo/Zacks.com
Investors Need a Peephole Into FDA Offices
Motley Fool
Cell Therapeutics-FDA set early June pixantrone meeting
bizjournals.com

